LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDYE. Morand, Shalabh Singhal, Nikolay Delev et al.|Annals of the Rheumatic Diseases|2022Cited by 19
PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial designU Ranganathan, Vaishali Shah, JT Merrill et al.|Unknown|2022Cited by 3
PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trialCristina Arriens, Ronald F Van Vollenhoven, Thomas Wegman et al.|Unknown|2026Cited by 0